Determinants of Red Cell Distribution Width (RDW) in Cardiorenal Patients
| Autor: | Pieter A. Doevendans, Mireille E. Emans, Karien van der Putten, Branko Braam, Karlijn L. van Rooijen, Wouter W. van Solinge, Dorine W. Swinkels, Maarten J. Cramer, Carlo A. J. M. Gaillard, Rob J. Kraaijenhagen |
|---|---|
| Přispěvatelé: | Nephrology, ICaR - Ischemia and repair, University of Groningen, Groningen Kidney Center (GKC) |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Erythrocyte Indices
Male CHRONIC KIDNEY-DISEASE medicine.medical_specialty HEMODIALYSIS Erythrocytes Anemia Drug Resistance SERUM Hepcidin Internal medicine hemic and lymphatic diseases medicine PROGNOSTIC MARKER Humans Iron metabolism [IGMD 7] iron metabolism Prospective Studies OLDER-ADULTS Erythropoietin Aged Cell Size Soluble transferrin receptor Aged 80 and over Heart Failure HEART-FAILURE PATIENTS biology business.industry MORTALITY Red blood cell distribution width medicine.disease EUROPEAN-SOCIETY Endocrinology IRON STATUS Heart failure biology.protein Kidney Failure Chronic Female Hemoglobin hepcidin Cardiology and Cardiovascular Medicine business medicine.drug Kidney disease |
| Zdroj: | Journal of Cardiac Failure, 17, 626-33 Journal of Cardiac Failure, 17, 8, pp. 626-33 Journal of Cardiac Failure, 17(8), 626-633. Churchill Livingstone JOURNAL OF CARDIAC FAILURE, 17(8), 626-633. Churchill Livingstone Emans, M E, van der Putten, K, van Rooijen, K L, Kraaijenhagen, R J, Swinkels, D, van Solinge, W W, Cramer, M J, Doevendans, P A F M, Braam, B & Gaillard, C A J M 2011, ' Determinants of Red Cell Distribution Width (RDW) in Cardiorenal Patients: RDW is Not Related to Erythropoietin Resistance ', Journal of Cardiac Failure, vol. 17, no. 8, pp. 626-633 . https://doi.org/10.1016/j.cardfail.2011.04.009 |
| ISSN: | 1071-9164 |
| DOI: | 10.1016/j.cardfail.2011.04.009 |
| Popis: | Contains fulltext : 97802.pdf (Publisher’s version ) (Closed access) BACKGROUND: Studies have shown that red cell distribution width (RDW) is related to outcome in chronic heart failure (CHF). The pathophysiological process is unknown. We studied the relationship between RDW and erythropoietin (EPO) resistance, and related factors such as erythropoietic activity, functional iron availability and hepcidin. METHODS AND RESULTS: In the Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome (EPOCARES) study, which investigates the role of EPO in 54 iron-supplemented anemic patients with CHF and chronic kidney disease (CKD) (n = 35 treated with 50 IU/kg/wk Epopoetin beta, n = 19 control), RDW was not associated with EPO resistance. We defined EPO resistance by EPO levels (r = 0.12, P = .42), the observed/predicted log EPO ratio (r = 0.12, P = .42), the increase in reticulocytes after 2 weeks of EPO treatment (r = -0.18, P = .31), and the increase of hemoglobin after 6 months of EPO treatment (r = 0.26, P = .35). However, RDW was negatively correlated with functional iron availability (reticulocyte hemoglobin content, r = -0.48, P < .001, and transferrin saturation, r = -0.39, P = .005) and positively with erythropoietic activity (soluble transferrin receptor, r = 0.48, P < .001, immature reticulocyte fraction, r = 0.36, P = .01) and positively with interleukin-6 (r = 0.48, P < .001). No correlation existed between hepcidin-25 and RDW. CONCLUSIONS: EPO resistance was not associated with RDW. RDW was associated with functional iron availability, erythropoietic activity, and interleukin-6 in anemic patients with CHF and CKD. 01 augustus 2011 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect